SIGY Chart by TradingView

Business Description

SIGY is a medical technology company focused on the treatment of life-threatening inflammatory conditions caused by cytokine storm syndrome. The company has developed a blood purification medical device, and is progressing towards receiving FDA approval to begin human clinical trials. Sigyn is headquartered in San Diego, California, and went public in October 2020.


FRC Analyst's Reports

Sigyn Therapeutics Inc. (OTC PINK: SIGY) – A Potential Solution for The Primary Cause of Death During the COVID-19 Pandemic – Initiating Coverage Feb. 25, 2022


Sigyn Therapeutics Appoints Donald J. Hillebrand, M.D. to its Scientific Advisory Board Apr. 26, 2022
Sigyn Therapeutics Appoints Ajay Verma, M.D., Ph.D. to its Scientific Advisory Board Mar. 31, 2022
Sigyn Therapeutics Announces Filing of 2021 Annual Report on Form 10-K Mar. 22, 2022
Sigyn Therapeutics™ Appoints H. David Humes, MD to Its Scientific Advisory Board Mar. 15, 2022
Sigyn Therapeutics Appoints Alexander S. Yevzlin, MD, FASN to Its Scientific Advisory Board Mar. 9, 2022

Investors are also interested in these companies: